Crossmark

Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China

Crossref DOI link: https://doi.org/10.1186/s12913-023-09600-7

Published Online: 2023-06-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Min

Liu, Lulu

Zhang, Lingli

Lin, Yunzhu

Lu, Xiaoxi

Yang, Hao

Ni, Jiaqi
Funding

Funding for this research was provided by:

New Fund of West China Second University Hospital (kx034)
License Information

Text and Data Mining valid from 2023-06-19

Version of Record valid from 2023-06-19
More Information

Article History

Received: 5 November 2022

Accepted: 25 May 2023

First Online: 19 June 2023

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below